Program
SP-102
A development code.
Its studies are mostly in Sciatica, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Semnur Pharmaceuticals | 21 open or running | phase 3since May 6, 2026 | Jul 9, 2018 | Nov 2028phase 3 · NCT07579351 |
| Scilex Pharmaceuticals | 10 open or running | phase 3since Dec 8, 2017 | Dec 8, 2017 | none ahead |
Also a collaborator on its studies: syngene and cromos-pharma-llc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 8, 2017First study: phase 3 study in SciaticaNew to Scilex PharmaceuticalsScilex Pharmaceuticals · NCT03372161 · 401 enrolled · United States
- Jul 9, 2018Semnur Pharmaceuticals's first study: phase 2 study in SciaticaNew to Semnur PharmaceuticalsSemnur Pharmaceuticals · NCT03613662 · 19 enrolled · United States
- May 6, 2026Phase 3 study in SciaticaPhase 3 reachedSemnur Pharmaceuticals · NCT07579351 · 755 planned
Ahead
- Nov 2028Primary completion: phase 3 study in SciaticaSemnur Pharmaceuticals · NCT07579351
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07579351Sciatica | 3 | Not yet recruiting | Semnur Pharmaceuticals | Nov 2028 | 755 |
| NCT03613662Sciatica · United States | 2 | Completed | Semnur Pharmaceuticals | Mar 15, 2019 | 19 |
| NCT03372161Sciatica · United States | 3 | Completed | Scilex Pharmaceuticals | Aug 20, 2021 | 401 |
How it is read
Names in the registry
- “SP-102”, 3 entries
Codes read as this program: SP102.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.